Chris Hill
Analyst · Stifel. Please go ahead
Thanks Larry. Before we review the financial performance for the quarter, the guidance we gave on our last call and past calls specifically excluded the impact of any FX gains or losses and assumed an effective tax rate of 20%. So accordingly, our discussion today excludes any foreign exchange gain or loss for current and prior periods. Additionally, the financial results for the second quarter of 2023 include, one, a tax benefit of approximately $11.6 million associated with the company's redomestication of the parent company from the Netherlands to the U.S., and two, a gain of approximately $2.9 million associated with proceeds received from company-owned life insurance policies and a reversal of previously recognized stock compensation expense for certain performance share awards which are no longer expected to vest. These items have also been excluded from our discussion of the financial results. Now looking at the income statement. Revenue was $127.9 million in the second quarter, flat compared to the prior quarter, and up almost 6% year-over-year. Sequentially, international upstream projects continue to expand. However, this increase was offset by a decrease in product sales as the U.S. onshore activity softened during the second quarter. The year-over-year growth in revenue was primarily associated with improved activity on international upstream projects and also higher levels of activity in the U.S. when compared to last year. Of this revenue, service revenue, which is more international, was $93.3 million for the quarter, up over 2% sequentially, and up over 9% from last year. International service revenue was up 4% sequentially and up over 7% year-over-year as the activity on projects outside the U.S. continues to build across multiple regions. Additionally, service revenue associated with crude assay work performed in our European operations also had some recovery from the decrease last quarter. Service revenue in the U.S. market was flat sequentially, but up over 13% year-over-year, primarily due to high use of our diagnostic services in the U.S. land market. Product sales, which is more equally tied to North America and international activity, were $34.6 million for the quarter, down 7% sequentially, and down 2% from last year. Product sales in the U.S., decreased 3% sequentially, as activity in the U.S. land market, peaked in April, and softened in May and June. Our international product sales, which are typically larger bulk orders, and can vary from one quarter to another, were also down slightly this quarter compared to last quarter. Moving on to cost of services, ex-items for the quarter was approximately 76% of service revenue, and improvement from 78% in the prior quarter, and 80% compared to the prior year. We continue to see improvements in absorption of costs and utilization of our global laboratory network, and anticipate additional improvement with growth in service revenue. Cost of sales ex-items in the second quarter was 84% of revenue compared to 82% last quarter. The increase this quarter is a combination of reduced manufacturing efficiencies associated with lower activity in the U.S. land market and lower international sales. We anticipate improvement in the manufacturing absorption rate in future quarters in line with our projected growth in product sales. G&A ex-items for the quarter was $8.7 million, a decrease from prior quarter, which was $9.8 million. For 2023, we expect G&A ex-items to be approximately $39 million to $40 million. Appreciation and amortization for the quarter was $3.9 million, relatively flat compared to $4 million, flat quarter. EBIT ex-items for the quarter was $15.6 million, an increase of $1.1 million over last quarter, yielding an EBIT margin of 12.2%, which expanded 90 basis points sequentially, and 420 basis points from last year. Our operating income for the quarter on a GAAP basis was $18.9 million, which includes the $2.9 million gain mentioned earlier. Interest expense of $3.2 million decreased from $3.4 million last quarter. Income tax expense, and an effective tax rate of 20% and ex-items was $3.2 million for the quarter. On a GAAP basis, we recorded a tax benefit of $7.3 million for the quarter, which includes the $11.6 million tax benefit associated with the company's redemestication transaction that was completed on May 1. The effective tax rate will continue to be somewhat sensitive to the geographic mix of earnings across the globe, and the impact of items that discrete to each quarter, however, we continue to project the company's effective tax rate to be approximately 20%. Net income ex-items for the quarter was $9.8 million, up from $8.8 million last quarter, and $5.4 million from last year. On a GAAP basis, we recorded net income of $22.8 million for the quarter. Earnings per diluted share, ex-items was $0.21 for the quarter, up from $0.19 last quarter, and compared to last year, the significant improvement over the $0.12 in the second quarter of 2022. On a GAAP basis, earnings per diluted share was $0.48 for the quarter, up from $0.05 in the prior quarter. Turning to the balance sheet. Receivable was $106.8 million and decreased approximately $3.9 million from the prior quarter. Our DSOs for the second quarter improved slightly to 72 days from 73 days in last quarter. We anticipate that our DSO will continue improving as we work back towards a level of 70 days or lower in future quarters. Inventory at June 30 was $71.7 million, up approximately $4.3 million from last quarter end. Inventory returns for the quarter decreased to $1.7 from $1.9 last quarter. The increase in the quarter is a combined effect of a slowing U.S. land market and also building stock in certain international locations to serve us some long-term international contracts. On the liability side of the balance sheet, our long-term debt was $185 million at June 30, and considering cash of $26.2 million, net debt was $158.8 million or down $7.9 million from last quarter. The decrease in net debt this quarter was primarily driven by free cash flow generated from operations. Our leverage ratio improved to $1.85 at June 30 compared to $2.18 at last quarter. And we anticipate the leverage ratio will continue to increase during the remainder of 2023. As mentioned during our last call, the company issued $50 million of new senior notes, which funded on June 28 of 2023. The new notes were split into two tranches, 25 million in each tranche, which have a five-year and seven-year maturity. The proceeds from the notes were used to reduce the outstanding balance on our revolving credit facility. Therefore, at June 30, our debt is currently comprised of our senior notes at $185 million with no outstanding balance under our bank revolving credit facility, which has a borrowing capacity of $135 million. The company will continue applying free cash towards reducing debt until the company reaches its target leverage ratio of 1.5 times or lower. Additionally, as we previously announced on July 17, 2023, the company terminated the ATM program that we launched in June of 2022. No shares of the company's stock -- company's common stock was sold into the program. Looking at cash flow for the second quarter of 2023, cash flow from operating activities was approximately $8.8 million and after paying for $2.2 million of CapEx during the quarter, our free cash flow for the quarter was $6.6 million. We expect CapEx to modestly expand in the second half of 2023, but we'll continue to be aligned with activity levels. For the full year of 2023, we expect capital expenditures to be in the range of $11 million to $13 million, or we'll continue its strict capital discipline and asset-like business model with capital expenditures primarily targeted at growth opportunities and initiatives. Core Lab's operational leverage continues to provide the ability to grow revenue and profitability with minimal capital requirements. Capital expenditures have historically range from 2% to 4% of revenue, even during periods of significant growth. That same level of laboratory infrastructure, intellectual property and leverage exists in the business today. We believe evaluating a company's ability to generate free cash flow and free cash flow yield as an important metric for shareholders when comparing companies financial results, particularly for those shareholders who utilize discounted cash flow models to assess valuations. I want to turn it over to Gwen for an update on our guidance and outlook.